Current and future management of GIST.
Blanke
Charles
C
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use; D016227:Benzoquinones / Q000009:adverse effects / Q000627:therapeutic use; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D047029:Lactams, Macrocyclic / Q000009:adverse effects / Q000627:therapeutic use; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D000077157:Sorafenib; D000077210:Sunitinib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D001557:Benzenesulfonates; D016227:Benzoquinones; D007211:Indoles; D047029:Lactams, Macrocyclic; D010671:Phenylurea Compounds; D010879:Piperazines; D011725:Pyridines; D011743:Pyrimidines; D011758:Pyrroles; D009536:Niacinamide; C112765:tanespimycin; D000068877:Imatinib Mesylate; D000077157:Sorafenib; C498826:nilotinib; D000077210:Sunitinib